Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SNTS's Cash to Debt is ranked higher than
76% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SNTS: No Debt )
SNTS' s 10-Year Cash to Debt Range
Min: 4.78   Max: No Debt
Current: No Debt

Equity to Asset 0.74
SNTS's Equity to Asset is ranked higher than
78% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SNTS: 0.74 )
SNTS' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.74
Current: 0.74

0.1
0.74
Interest Coverage 59.86
SNTS's Interest Coverage is ranked higher than
58% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SNTS: 59.86 )
SNTS' s 10-Year Interest Coverage Range
Min: 11.82   Max: 9999.99
Current: 59.86

11.82
9999.99
F-Score: 7
Z-Score: 17.48
M-Score: -1.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.26
SNTS's Operating margin (%) is ranked higher than
85% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SNTS: 9.26 )
SNTS' s 10-Year Operating margin (%) Range
Min: -6148.81   Max: 19.79
Current: 9.26

-6148.81
19.79
Net-margin (%) 8.51
SNTS's Net-margin (%) is ranked higher than
86% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SNTS: 8.51 )
SNTS' s 10-Year Net-margin (%) Range
Min: -6045.62   Max: 18.62
Current: 8.51

-6045.62
18.62
ROE (%) 22.37
SNTS's ROE (%) is ranked higher than
96% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. SNTS: 22.37 )
SNTS' s 10-Year ROE (%) Range
Min: -288.41   Max: 68.45
Current: 22.37

-288.41
68.45
ROA (%) 11.33
SNTS's ROA (%) is ranked higher than
94% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SNTS: 11.33 )
SNTS' s 10-Year ROA (%) Range
Min: -416.61   Max: 24.45
Current: 11.33

-416.61
24.45
ROC (Joel Greenblatt) (%) 2134.60
SNTS's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. SNTS: 2134.60 )
SNTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17820.96   Max: 3901.83
Current: 2134.6

-17820.96
3901.83
Revenue Growth (%) 2.90
SNTS's Revenue Growth (%) is ranked higher than
77% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. SNTS: 2.90 )
SNTS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 233.2
Current: 2.9

0
233.2
EBITDA Growth (%) -14.60
SNTS's EBITDA Growth (%) is ranked higher than
70% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. SNTS: -14.60 )
SNTS' s 10-Year EBITDA Growth (%) Range
Min: -53.3   Max: 51.2
Current: -14.6

-53.3
51.2
EPS Growth (%) -20.60
SNTS's EPS Growth (%) is ranked higher than
68% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. SNTS: -20.60 )
SNTS' s 10-Year EPS Growth (%) Range
Min: -55.7   Max: 55.8
Current: -20.6

-55.7
55.8
» SNTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SNTS Guru Trades in Q1 2013

Jim Simons 2,548,943 sh (+9.78%)
Paul Tudor Jones 11,800 sh (-6.35%)
Steven Cohen 34,591 sh (-98.97%)
» More
Q2 2013

SNTS Guru Trades in Q2 2013

Jim Simons 2,684,843 sh (+5.33%)
Paul Tudor Jones 11,600 sh (-1.69%)
Steven Cohen 10,940 sh (-68.37%)
» More
Q3 2013

SNTS Guru Trades in Q3 2013

Joel Greenblatt 66,922 sh (New)
Steven Cohen 79,817 sh (+629.59%)
Paul Tudor Jones 23,000 sh (+98.28%)
Jim Simons 2,142,938 sh (-20.18%)
» More
Q4 2013

SNTS Guru Trades in Q4 2013

John Paulson 5,000,000 sh (New)
Mario Gabelli 392,700 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 2,136,038 sh (-0.32%)
Joel Greenblatt 25,257 sh (-62.26%)
» More
» Details

Insider Trades

Latest Guru Trades with SNTS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2013-12-31 New Buy0.79%$21.05 - $32.18 $ 31.9614%5000000
Mario Gabelli 2013-12-31 New Buy0.07%$21.05 - $32.18 $ 31.9614%392700
Joel Greenblatt 2013-12-31 Reduce -62.26%0.03%$21.05 - $32.18 $ 31.9614%25257
Joel Greenblatt 2013-09-30 New Buy0.05%$21.17 - $27.26 $ 31.9634%66922
George Soros 2011-09-30 Sold Out 0.0013%$2.49 - $3.39 $ 31.96941%0
George Soros 2011-06-30 Add 46.35%$3.03 - $3.48 $ 31.96892%28100
George Soros 2011-03-31 New Buy$3.14 - $3.69 $ 31.96863%19200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.40
SNTS's P/E(ttm) is ranked higher than
82% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. SNTS: 19.40 )
SNTS' s 10-Year P/E(ttm) Range
Min: 3.52   Max: 648
Current: 19.4

3.52
648
P/B 9.26
SNTS's P/B is ranked lower than
59% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SNTS: 9.26 )
SNTS' s 10-Year P/B Range
Min: 1.49   Max: 18.71
Current: 9.26

1.49
18.71
P/S 7.28
SNTS's P/S is ranked higher than
62% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. SNTS: 7.28 )
SNTS' s 10-Year P/S Range
Min: 0.49   Max: 21.18
Current: 7.28

0.49
21.18
PFCF 30.44
SNTS's PFCF is ranked higher than
60% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. SNTS: 30.44 )
SNTS' s 10-Year PFCF Range
Min: 3.39   Max: 167
Current: 30.44

3.39
167
EV-to-EBIT 26.74
SNTS's EV-to-EBIT is ranked lower than
56% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SNTS: 26.74 )
SNTS' s 10-Year EV-to-EBIT Range
Min: 1.2   Max: 116.1
Current: 26.74

1.2
116.1
Shiller P/E 122.24
SNTS's Shiller P/E is ranked lower than
62% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. SNTS: 122.24 )
SNTS' s 10-Year Shiller P/E Range
Min: 84.38   Max: 158.82
Current: 122.24

84.38
158.82

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.60
SNTS's Price/Net Cash is ranked lower than
72% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. SNTS: 24.60 )
SNTS' s 10-Year Price/Net Cash Range
Min: 2.81   Max: 517
Current: 24.6

2.81
517
Price/Net Current Asset Value 17.00
SNTS's Price/Net Current Asset Value is ranked lower than
64% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. SNTS: 17.00 )
SNTS' s 10-Year Price/Net Current Asset Value Range
Min: 2.72   Max: 27.5
Current: 17

2.72
27.5
Price/Tangible Book 10.20
SNTS's Price/Tangible Book is ranked lower than
63% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SNTS: 10.20 )
SNTS' s 10-Year Price/Tangible Book Range
Min: 2.42   Max: 161
Current: 10.2

2.42
161
Price/DCF (Projected) 6.60
SNTS's Price/DCF (Projected) is ranked lower than
62% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. SNTS: 6.60 )
SNTS' s 10-Year Price/DCF (Projected) Range
Min: 4.64   Max: 12.22
Current: 6.6

4.64
12.22
Price/Median PS Value 3.30
SNTS's Price/Median PS Value is ranked lower than
71% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SNTS: 3.30 )
SNTS' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 6.85
Current: 3.3

0.28
6.85
Price/Graham Number 2.70
SNTS's Price/Graham Number is ranked higher than
62% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. SNTS: 2.70 )
SNTS' s 10-Year Price/Graham Number Range
Min: 0.69   Max: 7.75
Current: 2.7

0.69
7.75
Earnings Yield (Greenblatt) 3.70
SNTS's Earnings Yield (Greenblatt) is ranked higher than
55% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SNTS: 3.70 )
SNTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 86.3
Current: 3.7

0.9
86.3
Forward Rate of Return (Yacktman) 0.15
SNTS's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SNTS: 0.15 )
SNTS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -30.8   Max: 0.4
Current: 0.15

-30.8
0.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TW4A.Germany
Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide